Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering if DANYELZA sales are accelerating, or how much cash Y-mAbs has left for its SADA PRIT trials? Biotech filings can bury answers inside pages of risk factors, clinical data tables, and licensing fine print. Stock Titan surfaces what matters immediately.
Our AI reads every 10-K, 10-Q, 8-K, and effective immediately shows you:
- AG真人官方-time alerts for Y-mAbs Form 4 insider transactions鈥攕pot executive stock moves before the market reacts.
- Concise explanations of each Y-mAbs quarterly earnings report 10-Q filing, including R&D spend and DANYELZA revenue trends.
- Clinical milestone tracking from 8-K material events explained鈥攌now when pivotal trial data or FDA feedback hits EDGAR.
If you have ever searched 鈥淵-mAbs SEC filings explained simply鈥� or 鈥渦nderstanding Y-mAbs SEC documents with AI,鈥� this page delivers. Stock Titan鈥檚 models translate technical jargon into clear takeaways: cash runway, royalty obligations, manufacturing agreements, and pipeline readouts. Use our side-by-side viewer to compare segments across years, export charts, or drill down to Y-mAbs executive stock transactions Form 4.
Whether you need a Y-mAbs annual report 10-K simplified for deep due diligence, a quick look at Y-mAbs proxy statement executive compensation, or an alert on the next Y-mAbs earnings report filing analysis, every document appears here within seconds of hitting EDGAR鈥攁lready summarized by AI, already linked to the numbers you care about.
Y-mAbs Therapeutics (YMAB) 10-Q, quarter ended 30 Jun 2025:
- Revenue: six-month net product revenue fell 5.5 % YoY to $39.9 m; total revenue $40.4 m (-5.4 %). U.S. contributed 69 %; Asia & LatAm offset weaker domestic demand.
- Profitability: gross profit $34.8 m (margin 86 % vs 88 %), but operating costs were cut 13.6 % to $46.9 m (lower R&D and SG&A). Net loss narrowed to $8.4 m (-47 %), EPS -$0.19 vs -$0.36.
- Cash flow & balance sheet: operating cash burn $5.3 m; cash & equivalents $62.3 m, projected to fund 鈮�12 months. Inventory rose to $28.9 m (portion re-classified long-term).
- Segments & product mix: Company now reports two segments鈥攃ommercial DANYELZA and Radio-immunotherapy (RIT) pipeline. DANYELZA remains sole marketed asset; royalty revenue from distributors $3.8 m YTD.
- Other items: announced 4 Aug 2025 merger agreement with Perseus BidCo US, Inc. (post-period); new 10-year HQ lease added $2.6 m ROU asset. No changes to milestone/royalty obligations with MSK/MIT; maximum unpaid milestones total $54.3 m.
Overall, YMAB delivered tighter cost control and higher interest income, partially offsetting a mid-single-digit sales decline. Liquidity appears adequate pending completion of the proposed merger and continued DANYELZA commercialization.
Y-mAbs Therapeutics (YMAB) has filed a Schedule 14D-9 in response to a proposed acquisition. Perseus BidCo US, Inc. will launch a cash tender offer at $8.60 per share for all outstanding YMAB common stock, to be followed by a Section 251(h) short-form merger that will leave the company as the surviving entity. The buyer鈥檚 wholly owned subsidiary, Yosemite Merger Sub, will be merged into YMAB immediately after successful completion of the tender, eliminating any need for a separate stockholder vote.
- Deal structure: all-cash offer; merger effected under Delaware law for speed and certainty.
- Key date: Merger Agreement signed 4 Aug 2025; internal communications to employees dated 6 Aug 2025.
- Next step: Purchaser will formally commence the tender offer; YMAB鈥檚 Board will issue its recommendation in subsequent filings.
This filing only includes two exhibits鈥攁n employee message and FAQ鈥攊ndicating the transaction is at the communications stage; no financial results or closing conditions are detailed.
Transaction overview: Y-mAbs Therapeutics, Inc. entered into a Merger Agreement dated August 4, 2025 with Perseus BidCo US, Inc. (Parent), Yosemite Merger Sub, Inc. (Purchaser) and Stark International Lux. Purchaser will commence a cash Tender Offer of $8.60 per Share for all outstanding common stock, without interest and subject to applicable withholding taxes. If successful, the Tender Offer will be followed by a merger under Section 251(h) of the Delaware General Corporation Law, with the Company surviving the Merger.
Communications included: This Schedule 14D-9 consists of communications dated August 5, 2025, incorporated as Exhibits 99.1鈥�99.6: a joint press release, an employee email, an investor/analyst letter, a patient and advocacy organization letter, a vendor/supplier letter, and a LinkedIn post.
FAQ
What is the current stock price of Y-Mabs Therapeutics (YMAB)?
What is the market cap of Y-Mabs Therapeutics (YMAB)?
